CJC-1295 mechanism: GHRH receptor agonism and the no-DAC pulse.

The CJC-1295 mechanism is clean and pharmacologically credible. It's a 29-residue synthetic copy of the body's own growth-hormone-releasing signal. It binds the same pituitary lock that signal does. The molecule is real. The clinical evidence for what people buy it for isn't.

This article covers the receptor pharmacology in detail — not the "boosts growth hormone" marketing shorthand. The sections below address the receptor biology, the pulse pattern the no-DAC form preserves, the albumin-binding mechanism behind the DAC form's long half-life, the ipamorelin pairing rationale, and the current state of the human evidence base.

A glossary first.

• The brain signal. A 44-amino-acid signal called growth-hormone-releasing hormone that directs the pituitary to release growth hormone.
• The receptor. The pituitary cell-surface receptor that this signal binds. CJC-1295 binds the same receptor.
• Somatotrophs. The pituitary cells that store and release growth hormone.
• DAC (Drug Affinity Complex). A molecular linker that binds albumin, the most abundant protein in circulation. It extends half-life from minutes to days.
• Pulsatile release. Growth hormone is released in bursts, not continuously. The pulse pattern is physiologically distinct from sustained elevation.

The pituitary cell is the target.

The hypothalamus sends the growth-hormone-releasing signal in pulses. Those pulses act on a receptor on pituitary somatotrophs, which respond by releasing growth hormone in matching pulses.

Inside the cell, the receptor activates an enzyme that produces a relay molecule called cAMP. The downstream effects include growth-hormone gene transcription, vesicle release, and somatotroph growth over time.

CJC-1295 binds this same receptor. The 2026 Rahman review in JAAOS Global Research groups it with sermorelin, tesamorelin, ipamorelin, and AOD-9604. They all activate the same downstream signaling. The receptor mechanism is identical to the natural signal. The differences are how long each molecule persists in circulation, not what it does at the cell.

Receptor binding triggers a growth-hormone pulse from the pituitary. A downstream protein (IGF-1) is subsequently produced by the liver over the next several hours. Negative feedback to the hypothalamus then suppresses further release. The full feedback loop remains intact.

That last point is the key mechanistic difference between CJC-1295 and exogenous synthetic growth hormone. Synthetic growth hormone bypasses the pituitary entirely and produces a flat, non-pulsatile elevation. CJC-1295 acts through the endogenous release machinery and preserves the pulsatile pattern.

CJC-1295 (no DAC)

GHRH analog 29 aa No DAC

The same compound cited across the receptor-mechanism reviews in this article. Lab-verified identity and purity. The no-DAC form preserves natural pulse dynamics for receptor-pharmacology studies.

View CJC-1295

Why the short half-life is a feature, not a bug.

The no-DAC version of CJC-1295 (also called Modified GRF 1-29, or Mod GRF) is the bare analog. No molecular hook. The 2021 Memdouh paper in Drug Testing and Analysis measured its half-life at around 30 minutes. That's similar to the natural signal it copies.

For studying pulse dynamics, 30 minutes is exactly the right timescale. Endogenous GH pulses peak and decay over similar intervals. The no-DAC analog produces a single clean pulse without overlapping the next physiological pulse. Researchers administer a defined dose, sample serum at known intervals, and observe a clean pulse-and-decay pattern that mirrors normal physiology.

The DAC variant has the opposite design philosophy. The "molecular hook" (technically a maleimidopropionic acid linker) chemically binds to free sulfur groups on albumin, the most abundant protein in circulation. That extends circulation time from minutes to ~8 days.

ConjuChem originally developed this version as a once-weekly dosing candidate for clinical use. The pharmacological consequence is sustained, near-constant receptor activation rather than pulses. That's fine for a sustained-elevation strategy. It also eliminates the pulsatile pattern that distinguishes GHRH analogs from synthetic growth hormone in the first place.

For studying receptor signaling on its own terms, the no-DAC form is the cleaner tool. The pulse is the physiological signal. Smoothing it out is a different experiment.

Why people pair it with ipamorelin.

CJC-1295 is frequently co-investigated with ipamorelin in both research settings and grey-market use. The mechanistic rationale is straightforward.

Two distinct receptors on the same pituitary somatotroph drive growth-hormone release through different intracellular signaling routes. CJC-1295 activates the cAMP route via GHRH-R. Ipamorelin activates a calcium-based route via GHSR-1a. Preclinical studies reported a larger GH pulse when both were administered together than either alone.

The 2026 Mayfield review in the American Journal of Sports Medicine notes that CJC-1295 paired with ipamorelin improved peak muscle force in mice with steroid-induced muscle loss. The review limits the conclusion to animal data. No parallel human trial exists.

This pattern recurs throughout the literature: a mechanistically coherent combination, supported by preclinical pharmacology, but not tested in humans for the indications grey-market protocols claim. The mechanism is plausible. The clinical translation is not validated.

The strange shape of the recent literature.

The most distinctive thing about CJC-1295's recent footprint is what's missing. The 2020 Sinha review on growth-hormone secretagogues cites the older clinical-pharmacology data showing dose-dependent growth-hormone increases in healthy adults receiving the DAC variant. It also notes that the scarcity of clinical data limits understanding of clinical roles.

That scarcity hasn't been remedied. No new randomized controlled trial of CJC-1295 for performance, body composition, or anti-aging has published in the 2020-2026 window. The bulk of recent work falls into two buckets:

The 2026 Coutinho critical review in Journal of Sports Medicine and Physical Fitness frames CJC-1295 as part of a "new era of doping." It points out that unregulated supply chains expose users to cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability without any controlled-trial validation of claimed benefits.

What the molecule does vs what the literature shows.

The honest framing separates two questions.

First: does the molecule do what its mechanism predicts? Does it bind the receptor and trigger a growth-hormone pulse? Yes. The older clinical-pharmacology data is consistent.

Second: does raising growth hormone this way produce the body-composition and anti-aging outcomes the marketing claims? That's the question with no published RCT answer.

CJC-1295 (no DAC)

10 mg ≥99% pure Lyophilized

Synthetic 29-aa GHRH analog without the DAC linker. The shorter half-life preserves natural pulse dynamics for receptor-mechanism research. COA available with each lot.

Learn more

How to read this literature.

The mechanism papers represent solid receptor pharmacology applied to a well-characterized target. The receptor biology is established. The no-DAC form's short half-life is useful for studying physiological pulse dynamics. The ipamorelin pairing rationale is mechanistically coherent.

Marketing literature around CJC-1295 circulates without the support of modern human RCT validation. The molecule sits on the WADA Prohibited List with reliably validated detection methods. The 2020 Sinha review's framing of CJC-1295 as "potent but underexplored" remains accurate as of 2026.